Quick Answer
Viking Therapeutics, Inc. reported Net Income of -$359.64 million for fiscal year 2025.
Viking Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$359.64M | -227.1% |
| 2024 | -$109.96M | -28.0% |
| 2023 | -$85.89M | -24.7% |
| 2022 | -$68.87M | -25.2% |
| 2021 | -$54.99M | -39.2% |
| 2020 | -$39.49M | -53.2% |
| 2019 | -$25.78M | -16.8% |
| 2018 | -$22.06M | -7.2% |
| 2017 | -$20.58M | -39.7% |
| 2016 | -$14.73M | +37.1% |
| 2015 | -$23.40M | -6.9% |
| 2014 | -$21.88M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$90.79M | -264.0% | -38.5% |
| June 30, 2025 | -$65.56M | -194.7% | -43.7% |
| March 31, 2025 | -$45.63M | -66.8% | -83.0% |
| September 30, 2024 | -$24.94M | -10.7% | -12.1% |
| June 30, 2024 | -$22.25M | -15.7% | +18.7% |
| March 31, 2024 | -$27.36M | -40.1% | -21.4% |
| September 30, 2023 | -$22.53M | -42.9% | -17.2% |
| June 30, 2023 | -$19.23M | -10.3% | +1.6% |
- Viking Therapeutics, Inc. showed a decrease of -227.1% in Net Income compared to the prior fiscal year.
- Over the 2014–2025 period, Viking Therapeutics, Inc.’s net income has declined by 1543.4% (from -$21.88 million to -$359.64 million).
- The most recent figure is from Viking Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: